For the full year sales increased 4.0% to 23.7 billions, with a net profit of 9.57 billions. Total debt: 34.0 billions. The company product's innovation is very intense, currenty has 10 firt-in-human molecules in clinical development.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
